NEW YORK (GenomeWeb) – In the wake of the first US Food and Drug Administration approval of a liquid biopsy test in June, stakeholders are grappling with the next steps in advancing additional clinical blood-based cancer tests under a changing landscape of regulatory oversight.

Representatives from liquid biopsy diagnostic firms, clinical researchers, FDA officials, payors, and drugmakers gathered on Tuesday for a joint FDA- and American Association for Cancer Research-sponsored workshop on the subject.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.